Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.

abstract：BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictiv...

journal_title：Thoracic cancer

authors： Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino T

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:This study was conducted to investigate the gene expression profiles associated with thymoma to better understand the molecular mechanism underlying the pathogenesis of thymoma. METHODS:Eight patients with thymomas (type A, AB, B1, and B2) and four controls with thymic cysts were analyzed using microarray p...

journal_title：Thoracic cancer

authors： Meng FJ,Wang S,Zhang J,Yan YJ,Wang CY,Yang CR,Guan ZY,Wang CL

更新日期：2019-05-01 00:00:00

abstract：BACKGROUND:We investigated the effect of micro-RNA 24 (miR-24) and WWOX on non-small cell lung cancer (NSCLC) cell proliferation and migration in vitro and in vivo. METHODS:We performed bioinformatics analysis and 3' untranslated region luciferase assay to investigate the direct target of miR-24. Proliferation, apopto...

journal_title：Thoracic cancer

authors： Wang XH,Gan CZ,Xie JY

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:Previous studies have reported that soluble fms-like tyrosine kinase-1 (sFlt-1) possesses anti-tumor effects by inhibiting angiogenesis in many cancers. Exosomes can be engineered as delivery vehicles for transferring functional biomolecules, such as proteins, lipids, and nucleic acids (DNA, mRNA, and miRNA)...

journal_title：Thoracic cancer

authors： Hao D,Li Y,Zhao G,Zhang M

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Increasing evidence has demonstrated that circular RNAs (circRNAs) may play an important role in oncogenesis and tumor development; however, their role in lung adenocarcinoma (LUAD) remains unclear. We identified the differentially expressed circRNAs in LUAD and investigated the potential mechanisms for canc...

journal_title：Thoracic cancer

authors： Li S,Sun X,Miao S,Lu T,Wang Y,Liu J,Jiao W

更新日期：2018-08-01 00:00:00

abstract：:SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

journal_title：Thoracic cancer

authors： Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

更新日期：2019-12-01 00:00:00

abstract：:Immune checkpoint inhibitors (ICIs) have been widely used in the management of malignant tumors. Programmed death 1 (PD-1)/PD-1 ligand (PD-L1) inhibitors have been introduced to treat non-small cell lung cancer (NSCLC) in recent years. Currently, PD-1/PD-L1 inhibitors are considered to have minor side effects and do n...

journal_title：Thoracic cancer

authors： Lu M,Zhang L,Li Y,Wang H,Guo X,Zhou J,Duan L,Si X,Xu Y,Zhang L

更新日期：2020-03-01 00:00:00

abstract：:A mediastinal germ cell tumor with a sarcomatous component is extremely rare and is accompanied by a poor prognosis. Clinical and radiologic diagnosis is very difficult. Herein, we report a rare case of anterior mediastinal malignant teratoma containing a growing liposarcomatous component and detail the diagnostic pro...

journal_title：Thoracic cancer

authors： Lee HJ,Seon HJ,Choi YD

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...

journal_title：Thoracic cancer

authors： Zhai X,Hong R,Fan Y,Yuan P,Wang J,Sang D,Chen J,Zhao C,Ou K,Ma F,Xu B

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...

journal_title：Thoracic cancer

authors： Gao HJ,Shang XB,Gong L,Zhang HD,Ren P,Shi GD,Wei YC,Yu ZT

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported. METHODS:Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in thr...

journal_title：Thoracic cancer

authors： Zhang YW,Chen QQ,Cao J,Xu LQ,Tang X,Wang J,Zhang J,Dong LX

更新日期：2019-03-01 00:00:00

abstract：BACKGROUND:Sphingosine 1-phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, a...

journal_title：Thoracic cancer

authors： Tang X,Chen H,Chen G,Duan C,Fan Q,Li H,Wang Y,Li Z,Shi W,Liu Y

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:To distinguish early-stage lung cancer from benign disease in pulmonary nodules, especially lesions with ground-glass opacity (GGO), we assessed gene mutations of ctDNA in peripheral blood using targeted next-generation sequencing (NGS). METHODS:Single pulmonary nodule patients without mediastinal lymph nod...

journal_title：Thoracic cancer

authors： Jiang N,Zhou J,Zhang W,Li P,Liu Y,Shi H,Zhang C,Wang Y,Zhou C,Peng C,Zhang W,Hao Y,Sun Q,Li Y,Zhao X

更新日期：2020-11-16 00:00:00

abstract：BACKGROUND:The standard of care for fit locally advanced non-small cell lung cancer (NSCLC) patients is concurrent chemoradiotherapy (CCRT). However, in a subset of patients with lung adenocarcinoma with mutant EGFR (LA-mEGFR), the role of EGFR-tyrosine kinase inhibitors (TKIs) is not clear. We compared CCRT versus TKI...

journal_title：Thoracic cancer

authors： Hsia TC,Liang JA,Li CC,Chien CR

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

journal_title：Thoracic cancer

authors： Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Osimertinib (AZD9291) is a third-generation EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance to osimertinib is inevitable. METHO...

journal_title：Thoracic cancer

authors： Hayakawa D,Takahashi F,Mitsuishi Y,Tajima K,Hidayat M,Winardi W,Ihara H,Kanamori K,Matsumoto N,Asao T,Ko R,Shukuya T,Takamochi K,Hayashi T,Suehara Y,Takeda Nakamura I,Ueno T,Kohsaka S,Mano H,Takahashi K

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

journal_title：Thoracic cancer

authors： Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Breast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control. METHODS:Pooled da...

journal_title：Thoracic cancer

authors： Zuo TT,Zheng RS,Zeng HM,Zhang SW,Chen WQ

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Few studies have been conducted on the relationship between chronic periodontitis and postoperative pneumonia (POP) in patients with lung and esophageal cancer. Furthermore, it remains controversial as to whether improving the periodontal condition of patients with lung and esophageal cancer before surgery r...

journal_title：Thoracic cancer

authors： Jia C,Luan Y,Li X,Zhang X,Li C

更新日期：2021-01-24 00:00:00

abstract：BACKGROUND:Uniportal video-assisted thoracoscopic surgery (VATS) is being more widely used in lung cancer, yet reports on its application in pneumonectomies are limited. This study aimed to evaluate the safety and feasibility of uniportal video-assisted thoracoscopic left pneumonectomy for lung cancer. METHODS:A serie...

journal_title：Thoracic cancer

authors： Li J,Xue Q,Gao Y,Mao Y,Zhao J,Gao S

更新日期：2021-01-06 00:00:00

abstract：BACKGROUND:Non-small-cell lung cancer (NSCLC) is the most lethal type of cancer. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been identified as crucial regulators in the development of NSCLC. The aim of our study was to explore the molecular mechanism of SNHG1 to enable better treatment for NSCLC patient...

journal_title：Thoracic cancer

authors： Li X,Zheng H

更新日期：2020-02-01 00:00:00

abstract：:Both crizotinib and osimertinib have been reported to have an adverse effect of interstitial pneumonitis in the treatment of non-small cell lung cancer (NSCLC). Here, we report the case of a 60-year-old male patient with advanced NSCLC resistant to osimertinib. Crizotinib was administered in combination with osimertin...

journal_title：Thoracic cancer

authors： Cheng Y,Yu Q,Xiong Y,Guo C,Nie L

更新日期：2021-01-12 00:00:00

abstract：:A 60-year-old woman was urgently admitted to our hospital because of vertigo and left hemiplegia. Laboratory examination showed thrombocytopenia, high levels of D-dimer and carcinoembryonic antigen. Brain magnetic resonance imaging (MRI) revealed multiple bilateral cerebral infarctions. Chest computed tomography (CT) ...

journal_title：Thoracic cancer

authors： Nakano Y,Koide N,Koyama Y,Nitta K,Koizumi T

更新日期：2020-12-21 00:00:00

abstract：:Pleomorphic adenoma is the most common type of salivary gland tumor. Although it rarely affects the trachea and bronchus, it usually grows in the airway and presents as an endobronchial mass. We recently experienced a case of pleomorphic adenoma originating in the bronchus and growing outward into the mediastinum. We ...

journal_title：Thoracic cancer

authors： Lee YK,Kim YH,Kim GY,Youn HC

更新日期：2014-01-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in microwave ablation (MWA) ...

journal_title：Thoracic cancer

authors： Guo R,Li Y,Bie Z,Li B,Li X

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

journal_title：Thoracic cancer

authors： Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

更新日期：2019-04-01 00:00:00

abstract：:Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...

journal_title：Thoracic cancer

authors： Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda T

更新日期：2020-09-01 00:00:00

abstract：:Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

journal_title：Thoracic cancer

authors： Shan Q,Wang H,Han X,Guo J,Wang Z

更新日期：2020-10-01 00:00:00

abstract：:Pulmonary pleomorphic carcinoma (PPC) is a very rare type of primary lung cancer with an aggressive clinical course. Few reports have documented therapeutic options for PPC with EGFR mutations. Herein, we report a case of PPC with EGFR mutation treated with EGFR-tyrosine kinase inhibitors (TKIs). A 65-year-old Japanes...

journal_title：Thoracic cancer

authors： Masuda K,Tokito T,Azuma K,Yanagida E,Nakamura M,Naito Y,Matsuo N,Ishii H,Yamada K,Akiba J,Hoshino T

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:  To evaluate the conditions of palliative chemotherapy in terminally ill patients with advanced non-small cell lung cancer (NSCLC), and to discuss the potential factors that affect the prognosis of these patients. METHODS:  All 205 terminally ill patients with advanced NSCLC, who died in our hospital durin...

journal_title：Thoracic cancer

authors： Yang D,Qiu M,Zou LQ,Zhang W,Jiang Y,Zhang DY,Yan X

更新日期：2013-05-01 00:00:00